

Salvatore Oddo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1103096/salvatore-oddo-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

98
papers

20,991
citations

63
h-index

105
g-index

105
ext. papers

23,556
ext. citations

7.4
avg, IF

6.56
L-index

#	Paper	IF	Citations
98	Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). <i>Autophagy</i> , 2021 , 17, 1-382	10.2	440
97	Maternal choline supplementation ameliorates Alzheimer's disease pathology by reducing brain homocysteine levels across multiple generations. <i>Molecular Psychiatry</i> , 2020 , 25, 2620-2629	15.1	24
96	Lifelong choline supplementation ameliorates Alzheimer's disease pathology and associated cognitive deficits by attenuating microglia activation. <i>Aging Cell</i> , 2019 , 18, e13037	9.9	40
95	Differential activation of the mTOR/autophagy pathway predicts cognitive performance in APP/PS1 mice. <i>Neurobiology of Aging</i> , 2019 , 83, 105-113	5.6	16
94	Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice. <i>Molecular Neurobiology</i> , 2019 , 56, 8364-8375	6.2	9
93	Current Status of Healthy Aging and Dementia Research: A Symposium Summary. <i>Journal of Alzheimer's Disease</i> , 2019 , 72, S11-S35	4.3	4
92	Temporal and regional progression of Alzheimer's disease-like pathology in 3xTg-AD mice. <i>Aging Cell</i> , 2019 , 18, e12873	9.9	87
91	Genetically reducing mTOR signaling rescues central insulin dysregulation in a mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018 , 68, 1	5.6	24
90	Acute tau knockdown in the hippocampus of adult mice causes learning and memory deficits. <i>Aging Cell</i> , 2018 , 17, e12775	9.9	38
89	Paving the Way for New Clinical Trials for Alzheimer's Disease. <i>Biological Psychiatry</i> , 2017 , 81, 88-89	7.9	2
88	Genetic reduction of Nrf2 exacerbates cognitive deficits in a mouse model of Alzheimer's disease. <i>Human Molecular Genetics</i> , 2017 , 26, 4823-4835	5.6	53
87	Necroptosis activation in Alzheimer's disease. <i>Nature Neuroscience</i> , 2017 , 20, 1236-1246	25.5	173
86	Dyrk1 inhibition improves Alzheimer's disease-like pathology. <i>Aging Cell</i> , 2017 , 16, 1146-1154	9.9	50
85	[P2177]: NECROPTOSIS AS A NOVEL MECHANISM UNDERLYING NEURONAL LOSS IN ALZHEIMER'S DISEASE 2017 , 13, P674-P674		
84	Central insulin dysregulation and energy dyshomeostasis in two mouse models of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017 , 58, 1-13	5.6	47
83	p62 improves AD-like pathology by increasing autophagy. <i>Molecular Psychiatry</i> , 2017 , 22, 865-873	15.1	74
82	mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017 , 13, 152-167	1.2	48

81	Pim1 inhibition as a novel therapeutic strategy for Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2016 , 11, 52	19	20
80	Identification of learning-induced changes in protein networks in the hippocampi of a mouse model of Alzheimer's disease. <i>Translational Psychiatry</i> , 2016 , 6, e849	8.6	10
79	Reducing Ribosomal Protein S6 Kinase 1 Expression Improves Spatial Memory and Synaptic Plasticity in a Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2015 , 35, 14042-56	6.6	69
78	Aberrant intracellular localization of H3k4me3 demonstrates an early epigenetic phenomenon in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015 , 36, 3121-3129	5.6	34
77	How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story. <i>Experimental Gerontology</i> , 2015 , 68, 51-8	4.5	81
76	The mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer's disease. <i>Npj Aging and Mechanisms of Disease</i> , 2015 , 1, 15008	5.5	45
75	Reduced protein turnover mediates functional deficits in transgenic mice expressing the 25 kDa C-terminal fragment of TDP-43. <i>Human Molecular Genetics</i> , 2015 , 24, 4625-35	5.6	25
74	Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer's disease pathology. <i>Neurobiology of Aging</i> , 2014 , 35, 1233-42	5.6	60
73	Accumulation of C-terminal fragments of transactive response DNA-binding protein 43 leads to synaptic loss and cognitive deficits in human TDP-43 transgenic mice. <i>Neurobiology of Aging</i> , 2014 , 35, 79-87	5.6	32
72	Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature. <i>Journal of Neuroscience</i> , 2014 , 34, 7988-98	6.6	130
71	Administration of a selective α adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014 , 35, 2726-2735	5.6	40
70	Oxidative damage and amyloid- β metabolism in brain regions of the longest-lived rodents. <i>Journal of Neuroscience Research</i> , 2014 , 92, 195-205	4.4	28
69	Genetic suppression of α -adrenergic receptors ameliorates tau pathology in a mouse model of tauopathies. <i>Human Molecular Genetics</i> , 2014 , 23, 4024-34	5.6	18
68	Glucocorticoids exacerbate cognitive deficits in TDP-25 transgenic mice via a glutathione-mediated mechanism: implications for aging, stress and TDP-43 proteinopathies. <i>Journal of Neuroscience</i> , 2013 , 33, 906-13	6.6	28
67	mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies. <i>Aging Cell</i> , 2013 , 12, 370-80	9.9	242
66	Amyloid beta and the longest-lived rodent: the naked mole-rat as a model for natural protection from Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013 , 34, 2352-60	5.6	55
65	α adrenergic receptor, protein kinase A (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways mediate tau pathology in Alzheimer disease models. <i>Journal of Biological Chemistry</i> , 2013 , 288, 10298-307	5.4	63
64	Autophagic/lysosomal dysfunction in Alzheimer's disease. <i>Alzheimers Research and Therapy</i> , 2013 , 5, 53	9	116

63	BACE1 elevation is involved in amyloid plaque development in the triple transgenic model of Alzheimer's disease: differential A β antibody labeling of early-onset axon terminal pathology. <i>Neurotoxicity Research</i> , 2012 , 21, 160-74	4.3	42
62	Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1 β and enhancing NMDA signaling. <i>Aging Cell</i> , 2012 , 11, 326-35	9.9	155
61	Cognitive decline typical of frontotemporal lobar degeneration in transgenic mice expressing the 25-kDa C-terminal fragment of TDP-43. <i>American Journal of Pathology</i> , 2012 , 180, 293-302	5.8	40
60	Chronic temporal lobe epilepsy is associated with enhanced Alzheimer-like neuropathology in 3 \times Tg-AD mice. <i>PLoS ONE</i> , 2012 , 7, e48782	3.7	41
59	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012 , 8, 445-544.2	2783	
58	Sortilin is required for toxic action of A β oligomers (A β O): extracellular A β O trigger apoptosis, and intraneuronal A β O impair degradation pathways. <i>Life Sciences</i> , 2012 , 91, 1177-86	6.8	19
57	The role of mTOR signaling in Alzheimer disease. <i>Frontiers in Bioscience - Scholar</i> , 2012 , 4, 941-52	2.4	131
56	Toxic role of K ⁺ channel oxidation in mammalian brain. <i>Journal of Neuroscience</i> , 2012 , 32, 4133-44	6.6	64
55	Methylene blue reduces A β levels and rescues early cognitive deficit by increasing proteasome activity. <i>Brain Pathology</i> , 2011 , 21, 140-9	6	143
54	Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. <i>Journal of Biological Chemistry</i> , 2011 , 286, 8924-32	5.4	119
53	The collagen chaperone HSP47 is a new interactor of APP that affects the levels of extracellular beta-amyloid peptides. <i>PLoS ONE</i> , 2011 , 6, e22370	3.7	9
52	Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. <i>PLoS ONE</i> , 2011 , 6, e25416	3.7	287
51	CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 22687-92	11.5	191
50	ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 3081-6	11.5	140
49	Experience-dependent regulation of vesicular zinc in male and female 3xTg-AD mice. <i>Neurobiology of Aging</i> , 2010 , 31, 605-13	5.6	13
48	Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. <i>Journal of Biological Chemistry</i> , 2010 , 285, 13107-20	5.4	625
47	Age-dependent changes in TDP-43 levels in a mouse model of Alzheimer disease are linked to A β oligomers accumulation. <i>Molecular Neurodegeneration</i> , 2010 , 5, 51	19	25
46	Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability. <i>Journal of Biological Chemistry</i> , 2009 , 284, 27416-24	5.4	118

45	Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. <i>Neurobiology of Disease</i> , 2009 , 34, 163-77	7.5	204
44	Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer's disease. <i>Journal of Neuroscience Research</i> , 2009 , 87, 1462-73	4.4	67
43	Genetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathology. <i>Brain Pathology</i> , 2009 , 19, 421-30	6	30
42	Validation of a 2-day water maze protocol in mice. <i>Behavioural Brain Research</i> , 2009 , 196, 220-7	3.4	66
41	Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease. <i>Neuropharmacology</i> , 2009 , 56, 808-13	5.5	78
40	Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: An in situ cerebral perfusion study. <i>Neurochemistry International</i> , 2009 , 55, 476-82	4.4	157
39	Amyloid deposits show complexity and intimate spatial relationship with dendrosomatic plasma membranes: an electron microscopic 3D reconstruction analysis in 3xTg-AD mice and aged canines. <i>Journal of Alzheimer's Disease</i> , 2009 , 16, 315-23	4.3	18
38	Increased intraneuronal resting [Ca ²⁺] in adult Alzheimer's disease mice. <i>Journal of Neurochemistry</i> , 2008 , 105, 262-71	6	122
37	Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. <i>Brain Research</i> , 2008 , 1207, 225-36	3.7	171
36	The ubiquitin-proteasome system in Alzheimer's disease. <i>Journal of Cellular and Molecular Medicine</i> , 2008 , 12, 363-73	5.6	178
35	Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. <i>American Journal of Pathology</i> , 2008 , 173, 1768-82	5.8	167
34	Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. <i>Journal of Neuroscience</i> , 2008 , 28, 12163-75	6.6	110
33	Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. <i>PLoS ONE</i> , 2008 , 3, e2935	3.7	260
32	Congo red and thioflavin-T analogs detect Abeta oligomers. <i>Journal of Neurochemistry</i> , 2008 , 104, 457-68		165
31	Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid. <i>Neuroscience and Biobehavioral Reviews</i> , 2007 , 31, 125-47	9	175
30	Intracellular amyloid-beta in Alzheimer's disease. <i>Nature Reviews Neuroscience</i> , 2007 , 8, 499-509	13.5	1474
29	Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice. <i>Journal of Neurochemistry</i> , 2007 , 102, 1053-63	6	67
28	Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. <i>Journal of Neurochemistry</i> , 2007 , 103, 1132-44	6	136

27	Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. <i>Neurobiology of Disease</i> , 2007 , 28, 76-82	7.5	208
26	Enhanced ryanodine-mediated calcium release in mutant PS1-expressing Alzheimer τ mouse models. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1097, 265-77	6.5	90
25	Neural stem cells improve memory in an inducible mouse model of neuronal loss. <i>Journal of Neuroscience</i> , 2007 , 27, 11925-33	6.6	125
24	Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. <i>Journal of Neuroscience</i> , 2007 , 27, 13357-65	6.6	243
23	Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. <i>American Journal of Pathology</i> , 2007 , 170, 1669-75	5.8	163
22	The role of nicotinic acetylcholine receptors in Alzheimer τ disease. <i>Journal of Physiology (Paris)</i> , 2006 , 99, 172-9		100
21	Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. <i>Journal of Biological Chemistry</i> , 2006 , 281, 39413-23	5.4	227
20	Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer τ disease. <i>Journal of Neuroscience</i> , 2006 , 26, 13384-9	6.6	125
19	Enhanced ryanodine receptor recruitment contributes to Ca ²⁺ disruptions in young, adult, and aged Alzheimer τ disease mice. <i>Journal of Neuroscience</i> , 2006 , 26, 5180-9	6.6	261
18	Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. <i>Journal of Biological Chemistry</i> , 2006 , 281, 1599-604	5.4	303
17	A dynamic relationship between intracellular and extracellular pools of Abeta. <i>American Journal of Pathology</i> , 2006 , 168, 184-94	5.8	189
16	M1 receptors play a central role in modulating AD-like pathology in transgenic mice. <i>Neuron</i> , 2006 , 49, 671-82	13.9	348
15	Alzheimer τ disease: Abeta, tau and synaptic dysfunction. <i>Trends in Molecular Medicine</i> , 2005 , 11, 170-6	11.5	331
14	Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. <i>Neurobiology of Aging</i> , 2005 , 26, 645-54	5.6	269
13	Intraneuronal Abeta causes the onset of early Alzheimer τ disease-related cognitive deficits in transgenic mice. <i>Neuron</i> , 2005 , 45, 675-88	13.9	1007
12	Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer τ disease mice. <i>Journal of Neuroinflammation</i> , 2005 , 2, 23	10.1	173
11	Enhanced caffeine-induced Ca ²⁺ release in the 3xTg-AD mouse model of Alzheimer τ disease. <i>Journal of Neurochemistry</i> , 2005 , 94, 1711-8	6	129
10	Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer τ disease. <i>Journal of Neuroscience</i> , 2005 , 25, 8843-53	6.6	514

9	Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer τ disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 3046-51	11.5	155
8	Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. <i>Neuron</i> , 2004 , 43, 321-32	13.9	670
7	Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia. <i>Journal of Clinical Investigation</i> , 2004 , 113, 582-590	15.9	70
6	Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. <i>Journal of Clinical Investigation</i> , 2004 , 114, 121-130	15.9	332
5	Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia. <i>Journal of Clinical Investigation</i> , 2004 , 113, 582-90	15.9	51
4	Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. <i>Journal of Clinical Investigation</i> , 2004 , 114, 121-30	15.9	231
3	Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer τ disease. <i>Neurobiology of Aging</i> , 2003 , 24, 1063-70	5.6	736
2	Triple-transgenic model of Alzheimer τ disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. <i>Neuron</i> , 2003 , 39, 409-21	13.9	3031
1	Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 6334-9	11.5	91